Drotrecogin alfa (activated)...a sad final fizzle to a roller-coaster party (Q27025096)

Crossref

language of work or name

1 reference

6 February 2012

6 references

18 November 2019

27 November 2019

21 December 2019

1 February 2021

7 February 2024

6 references

18 November 2019

27 November 2019

21 December 2019

1 February 2021

7 February 2024

16

1 reference

issue

1

1 reference

page(s)

107

1 reference

Efficacy and safety of recombinant human activated protein C for severe sepsis

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396243

Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396243

The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396243

Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396243

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396243

The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396243

Compliance with a sepsis bundle and its effect on intensive care unit mortality in surgical septic shock patients

31 May 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FCC11152

In silico design of clinical trials: a method coming of age.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FCC11152

A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396243

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

28 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/22309988

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Activated protein C and hospital mortality in septic shock: a propensity-matched analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22309988